The Biased GLP-1 Signal: Ecnoglutide’s 35% Edge Over Semaglutide Is the Opening Shot in Obesity’s Next Competitive War
Sciwind's ecnoglutide beat semaglutide by 35% on weight loss in a head-to-head trial—and it signals a coming wave of...
Novo Nordisk’s Zenagamtide Isn’t Chasing Ozempic — It’s Trying to Make Tirzepatide Obsolete
Novo Nordisk's zenagamtide hit 14.6% weight loss and 89.1% A1C control in Phase 2. Here's what the ADA 2026...
mRNA 2.0 Is Not a Science Story — It’s a $31 Billion Platform Bet That Most Pipelines Aren’t Priced For
Nature Reviews Drug Discovery maps mRNA's expansion into enzyme replacement and cancer immunotherapy—here's what it means for pipeline valuations...
J&J’s Nipocalimab Data Signals the FcRn Gold Rush Has a Real Leader
J&J's nipocalimab cut SLE disease activity in Phase 2 JASMINE—and with Phase 3 already recruiting, FcRn blockade is becoming...
J&J’s PROTEUS Data Doesn’t Just Beat the Standard of Care — It Buries It
J&J's Phase 3 PROTEUS trial shows apalutamide before and after surgery cuts metastasis or death risk in high-risk prostate...
The Regulatory Data Gap Is Now a Competitive Moat — and Most Sponsors Are on the Wrong Side of It
Nature Reviews Drug Discovery's 2026 RWE framework signals a regulatory inflection point: sponsors who master data infrastructure will compress...
The China Oncology Pipeline Is Going Global — And Pfizer Just Fired the Starting Gun
Pfizer's deal with Innovent Biologics joins a pattern of Western pharma betting on Chinese oncology pipelines to fill post-LOE...
The $4 Billion AI Drug Discovery Bet Has a Hidden Ceiling No One Is Pricing In
AI drug discovery attracted $4B in 2024 VC funding, but Phase 3 attrition, payer skepticism, and regulatory opacity threaten...
The Triple Threat: Incretin Multi-Agonists Are About to Redraw the $77B Obesity Map
Nature Reviews flags incretin multi-agonist reversal of obesity and diabetes — Lilly's retatrutide Phase 3 data signals the GLP-1...
The Pricing Policy Mirage: Three Signals That Washington’s Drug Cost Crusade Is Reshaping Pharma Strategy Without Fixing Prices
Trump's executive orders and IRA negotiations promise relief, but branded drug prices rose 4.5% in 2024 and U.S. drugs...